Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?

Background: Consolidation systemic therapy (ST) given after concurrent radiotherapy (RT) and ST (RT-ST) is frequently practiced in locally advanced inoperable nonsmall cell lung cancer (NSCLC). Little is known, however, about the fate of patients achieving different responses after concurrent phases...

Full description

Bibliographic Details
Main Authors:	Branislav Jeremić, Elene Mariamidze, Inga Shoshiashvili, Ivane Kiladze
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Current Oncology
Subjects:	locally advanced disease inoperable nonsmall cell lung cancer concurrent radiotherapy and systemic therapy consolidation systemic therapy chemotherapy targeted therapy
Online Access:	https://www.mdpi.com/1718-7729/29/11/656

Similar Items

Comparison of radiation therapy alone and concurrent chemoradiation therapy for in operable cervical cancer
by: Md. Zillur Rahman Bhuiyan, et al.
Published: (2016-08-01)

Palliative Radiation Therapy for Symptomatic Control of Inoperable Renal Cell Carcinoma
by: Anatoly Nikolaev, et al.
Published: (2016-01-01)

IMRT in the treatment of locally advanced or inoperable NSCLC in the pre-durvalumab era: clinical outcomes and pattern of relapses, experience from the Oscar Lambret Center
by: Thomas Le Roy, et al.
Published: (2023-09-01)

Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis
by: Po-Lung Cheng, et al.
Published: (2023-04-01)

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis
by: Yuemei Sun, et al.
Published: (2020-07-01)

Individualized treatment decision model for inoperable elderly esophageal squamous cell carcinoma based on multi-modal data fusion
by: Yong Huang, et al.
Published: (2023-10-01)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
by: Marta Opalińska, et al.
Published: (2021-11-01)

Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up
by: Elisabetta Parisi, et al.
Published: (2019-06-01)

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
by: Arafat Tfayli, et al.
Published: (2020-11-01)

Identifying Prognostic Groups Using Machine Learning Tools in Patients Undergoing Chemoradiation for Inoperable Locally Advanced Nonsmall Cell Lung Carcinoma
by: Anjali K. Pahuja, et al.
Published: (2019-07-01)

Long-term survival of two patients with inoperable post-irradiation osteosarcoma treated with carbon-ion radiotherapy: a case report
by: Shintaro Shiba, et al.
Published: (2022-04-01)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
by: Kumar Prabhash
Published: (2019-01-01)

Clinicopathological factors and multimodality treatment for nonsmall cell lung carcinoma in a government tertiary care center – A benchmarking approach
by: Shradha Parameswaran, et al.
Published: (2023-01-01)

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
by: J.B. Sorensen, et al.
Published: (2011-03-01)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
by: Vanita Noronha, et al.
Published: (2020-01-01)

Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer—A Single-Center Experience and Review of the Literature
by: Nathalie Arians, et al.
Published: (2020-08-01)

Immunotherapy in inoperable stage III non-small cell lung cancer: a review
by: Natasha A Jain, et al.
Published: (2019-06-01)

Role of gender in the survival of surgical patients with nonsmall cell lung cancer
by: Nóris C Scaglia, et al.
Published: (2013-01-01)

Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
by: Xiaojie Xia, et al.
Published: (2022-09-01)

Prospective Evaluation of Quality of Life and Functional Outcomes after Carbon Ion Radiotherapy for Inoperable Bone and Soft Tissue Sarcomas
by: Shuichiro Komatsu, et al.
Published: (2021-05-01)

Results of the inoperable and operable with aortic valve endocarditis
by: Jing-bin Huang, et al.
Published: (2024-01-01)

Bronchial biopsy specimen as a surrogate for DNA methylation analysis in inoperable lung cancer
by: Sang-Won Um, et al.
Published: (2017-12-01)

Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme
by: Georgios Chatzikonstantinou, et al.
Published: (2019-06-01)

Reduction of resection volume in patients with non-small cell lung cancer after neoadjuvant chemoand photodynamic therapy
by: A. L. Akopov, et al.
Published: (2017-10-01)

Inoperable Bowel Obstruction in Ovarian Cancer: Prevalence, Impact and Management Challenges
by: Gonzalez-Ochoa E, et al.
Published: (2022-12-01)

Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database
by: Zhu X, et al.
Published: (2018-05-01)

Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial
by: Chengcheng Fan, et al.
Published: (2024-03-01)

Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy
by: Steven Du, et al.
Published: (2022-06-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: Shahriari Ahmadi A, et al.
Published: (2004-08-01)

Out-Patient Consolidation Therapy in Patients with AML by Mitoxan-trone, Etoposide and Cytarabine
by: A Shahriari Ahmadi, et al.
Published: (2004-03-01)

CT-guided percutaneous microwave ablation of pulmonary malignancies: Results in 69 cases
by: Lu Qiang, et al.
Published: (2012-05-01)

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
by: Jun Ni, et al.
Published: (2016-01-01)

RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment
by: Andrea Emanuele Guerini, et al.
Published: (2022-05-01)

The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer
by: Angelina Carey-Love, et al.
Published: (2021-02-01)

Radiotranscriptomics signature‐based predictive nomograms for radiotherapy response in patients with nonsmall cell lung cancer: Combination and association of CT features and serum miRNAs levels
by: Liyuan Fan, et al.
Published: (2020-07-01)

Pre-treatment optimization with pulmonary rehabilitation in lung cancer: Making the inoperable patients operable
by: Ira Goldsmith, et al.
Published: (2021-01-01)

Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective
by: Sehhoon Park
Published: (2023-03-01)

Disparate outcomes in nonsmall cell lung cancer by immigration status
by: Brittney Chau, et al.
Published: (2021-04-01)

Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation✰
by: Minh Phuong Vu, et al.
Published: (2023-01-01)

An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma
by: Hal Hirte, et al.
Published: (2021-03-01)